See more : Decarbonization Plus Acquisition Corporation (DCRBU) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- OneLogix Group Limited (OLG.JO) Income Statement Analysis – Financial Results
- Heart Tronics, Inc. (HRTT) Income Statement Analysis – Financial Results
- Bumrungrad Hospital Public Company Limited (BH-R.BK) Income Statement Analysis – Financial Results
- Rajesh Exports Limited (RAJESHEXPO.NS) Income Statement Analysis – Financial Results
- Advanced Wireless Semiconductor Company (8086.TWO) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 7.03M | 5.66M |
| Cost of Revenue | 1.71M | 1.05M | 586.00K |
| Gross Profit | -1.71M | 5.97M | 5.07M |
| Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
| Research & Development | 49.92M | 28.40M | 25.85M |
| General & Administrative | 12.48M | 8.01M | 6.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 12.48M | 8.01M | 6.15M |
| Other Expenses | 0.00 | -9.00K | -2.00K |
| Operating Expenses | 62.41M | 36.41M | 32.00M |
| Cost & Expenses | 62.41M | 36.41M | 32.00M |
| Interest Income | 2.28M | 565.00K | 1.00K |
| Interest Expense | 187.00K | 65.00K | 3.00K |
| Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
| EBITDA | -58.47M | -27.78M | -25.76M |
| EBITDA Ratio | 0.00% | -395.40% | -455.46% |
| Operating Income | -62.41M | -29.38M | -26.35M |
| Operating Income Ratio | 0.00% | -418.28% | -465.81% |
| Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
| Income Before Tax | -60.37M | -28.89M | -26.35M |
| Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
| Income Tax Expense | 0.00 | 56.00K | 1.00K |
| Net Income | -60.37M | -28.89M | -26.35M |
| Net Income Ratio | 0.00% | -411.29% | -465.88% |
| EPS | 0.00 | -1.12 | -1.02 |
| EPS Diluted | 0.00 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
| Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
The Schall Law Firm Is Looking Into Kyverna Therapeutics Inc For Possible Securities Law Violations And Shareholders Are Urged To Participate
Investors With Losses In Kyverna Therapeutics Inc Are Encouraged To Join The Schall Law Firm In A Securities Fraud Investigation
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Kyverna Therapeutics Inc For Securities Law Infractions
Kyverna Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Encouraged To Contribute
The Schall Law Firm Is Looking Into Kyverna Therapeutics Inc For Potential Securities Law Violations And Impacted Shareholders Are Invited To Participate
Kyverna Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Encouraged To Join
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
The Schall Law Firm Encourages Shareholders To Participate In The Investigation Of Kyverna Therapeutics Inc For Securities Law Violations
The Schall Law Firm Invites Investors To Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc
The Schall Law Firm Invites Investors To Join Kyverna Therapeutics Inc's Securities Fraud Investigation
Source: https://incomestatements.info
Category: Stock Reports